Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...

Reports Q4 revenue $0 vs. $301,590. “Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor ...

Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific ...